Key Points {#FPar1}
==========

No accumulation was observed after every 12 h (q12h) intravenous administration of up to 30 mg of dexlansoprazole for 5 days.No significant differences in baseline-adjusted median and mean intragastric pH, percentage of time with the intragastric pH above 4.0 \[TpH ≥ 4.0(%)\] and percentage of time with the intragastric pH above 6.0 \[TpH  ≥ 6.0(%)\] were observed between dexlansoprazole 15 mg and lansoprazole 30 mg during any intervals.Baseline-adjusted median and mean intragastric pH, TpH ≥ 4.0(%) and TpH ≥ 6.0(%) for dexlansoprazole 30 mg were significantly higher than those of dexlansoprazole 15 mg only 0--4 h after the first administration, suggesting that increasing the dose from 15 to 30 mg presented a transient better pH inhibition and had virtually little influence on whole-day gastric pH control.

Introduction {#Sec1}
============

Timely endoscopic haemostatic treatment and acid suppression with high-dose intravenous proton pump inhibitors (PPIs) are cornerstones in the successful management of patients with bleeding peptic ulcers \[[@CR1], [@CR2]\]. PPIs are supposed to inhibit gastric acid secretion by targeting the H+, K+-ATPase in the gastric parietal cells, and thus enhance platelet aggregation and clot formation and reduce fibrinolysis by elevated intragastric pH to control rebleeding from the peptic ulcer after initial endoscopic haemostasis \[[@CR3], [@CR4]\].

Lansoprazole, one of the six currently available PPIs in China, has been clinically used as a racemic mixture in several formulations. Due to the chiral center at the asymmetric sulfinyl group in its chemical structure, lansoprazole has two enantiomers---R-(+) and S-(−). The R-enantiomer is known as dexlansoprazole. Although the R and S isomers appeared to exhibit similar in vitro pharmacological properties, in vivo studies indicated that the gastric acid secretion inhibition activity of racemic lansoprazole was mainly from dexlansoprazole \[[@CR5]--[@CR7]\]. It showed that after a 60 mg oral dose of racemic lansoprazole in healthy Japanese subjects, the peak concentration of the R-isomer was 2.2- to 5.8-fold higher than that of the S-isomer, and the R/S ratios for the area under the concentration-time curve (AUC) was 5.8--12.7 \[[@CR5], [@CR6]\]. Following intravenous administration of racemic lansoprazole 30 mg, the mean clearance (CL) of the S-isomer was more than fourfold higher than that observed with the R-isomer, and the mean volume of distribution (*V*~d~) at steady-state for the S-isomer was approximately twice that of the R-isomer \[[@CR7]\]. Thus, after administration of lansoprazole, dexlansoprazole is the predominant isomer in the circulation as it has slower in vivo CL and greater systemic exposure than S-lansoprazole. Although higher plasma protein binding of dexlansoprazole, compared with the S-isomer \[[@CR8]\], will counteract the difference seen in total plasma concentrations of the enantiomers, pharmaceutical manufacturers have been trying to develop the single enantiomer of lansoprazole in order to improve drug activity. The first formulation of dexlansoprazole, a delayed-release capsule manufactured by Takeda Pharmaceuticals America, Inc. (DEXILANT^®^), was approved by the US FDA in 2009 for the healing of all grades of erosive esophagitis and for treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) \[[@CR9]\].

A novel injection formulation of dexlansoprazole has recently been developed for the treatment of acute peptic ulcer bleeding, or for patients with acid-related disease who are unable to swallow medications. A previous study to evaluate the safety and tolerability of dexlansoprazole injection after a single intravenous administration in healthy adults was carried out at our center from February to April 2017 (unpublished data). A total of 21 subjects received an intravenous infusion of dexlansoprazole ranging from 7.5 to 90 mg, while another seven subjects received placebo, demonstrating that a single dose of dexlansoprazole injection up to 90 mg was safe and well-tolerated. No dose-limiting toxicity (DLT) or serious adverse events (SAEs) were recorded. Subsequently, we carried out the current study to investigate the pharmacokinetic and pharmacodynamic characteristics of dexlansoprazole after single and multiple intravenous administrations in healthy Chinese adults, compared with the original lansoprazole injection.

Subjects and Methods {#Sec2}
====================

Study Drugs and Administration {#Sec3}
------------------------------

The investigational dexlansoprazole injection (15 mg per vial) was manufactured by Jiangsu Aosaikang Pharmaceutical Co., Ltd, China (batch number 160901, expiry date August 2018), and the active comparator (lansoprazole; 30 mg per vial) was Takepron^®^ injection, a commercially available original preparation from Takeda Pharmaceutical Company Limited, Japan (batch number H474, expiry date November 2017). Subjects received an intravenous infusion of dexlansoprazole or lansoprazole injection in a 100 mL sterile saline solution during a 30-min period using an infusion pump.

Subjects {#Sec4}
--------

Suitable Chinese male and female adults aged \> 18 years, with a body mass index ranging from 19 to 28 kg/m^2^, were recruited as healthy volunteers at the phase I unit, Research Center of Clinical Pharmacy, First Affliated Hospital, College of Medicine, Zhejiang University, China, in accordance with the Declaration of Helsinki and the Good Clinical Practice (GCP) guideline, during June to September 2017. All volunteers provided written informed consent to participate in the study after being well-informed about the study objectives, procedures, and possible risks. Subjects were determined to be in good health based on medical history, vital signs, physical examination, laboratory tests, 12-lead electrocardiography (ECG) and chest x-ray. Female participants of childbearing potential must have had a negative serum pregnancy test at screening, and agreed to use routinely adequate contraception. Male participants agreed to use adequate contraception and had no plans to donate sperm. Exclusion criteria were a positive *Helicobacter pylori* infection test; a history of known allergy or sensitivity to any drugs; a history of any clinically significant diseases, including (but not limited to) cardiovascular, respiratory, hepatic, renal, or gastrointestinal diseases; a history of alcohol or drug abuse; heavy smokers; participation in another study with an investigational drug within the last 3 months preceding this study; blood donation within the last 2 months (≥ 400 mL), or have a plan to donate blood within 1 month after completion of this study; and intake of any other drug that might influence the results of the trial during 2 weeks previous to the start of this study. Additional inclusion and exclusion criteria are detailed at ClinicalTrials.gov (<https://www.clinicaltrials.gov>; NCT03120273).

Study Design and Treatment {#Sec5}
--------------------------

This was a single center, open-label, single- and multiple-dose pharmacokinetic/pharmacodynamic study. The protocol was reviewed and approved by the Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University (approval number 2016-EC-81).

Five dosing groups were designed, i.e. 15 mg once daily (qd; group A), 15 mg every 12 h (q12h; group B), 30 mg qd (group C) and 30 mg q12h (group D) in the dexlansoprazole treatment arm for 5 days, and 30 mg q12h (group E) in an active comparator (lansoprazole) treatment arm for 5 days. Seventy volunteers were enrolled in this study, with 14 subjects in each group. All volunteers were confined to the phase I unit, beginning the evening before baseline intubation. On day 0, subjects received pH catheter placement for baseline 24-h intragastric pH monitoring. On day 1, after fasting for 10 h, a single intravenous dose of dexlansoprazole or lansoprazole was administered, and all subjects were sampled for pharmacokinetic analysis. Meanwhile, intragastric pH was continuously monitored for another 24 h. Subsequently, all subjects proceeded to multiple dosing as scheduled. On day 5, subjects received intubation transnasally, again for 24-h intragastric pH monitoring, and were sampled for pharmacokinetic analysis after the last morning dose. The volunteers were ambulatory, were prohibited from strenuous activity, smoking, alcohol, grapefruit juice and caffeine consumption, and were closely monitored by qualified staff throughout the entire confinement period of intubation and blood sampling. Water intake was strictly controlled on days 0, 1 and 5, and a standardized lunch and dinner were provided at 4 and 10 h postdosing on days 0, 1 and 5.

Blood Sampling and Analytical Determinations {#Sec6}
--------------------------------------------

A series of venous blood samples (4 mL) were collected in heparinized tubes at 0 (predose), 15, 30, and 45 min, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 h postdose on day 1 (first dose) and day 5 (last morning dose). Samples were centrifuged immediately at 4 °C, 3500 rpm for 10 min, and plasma was separated and stored at − 70 ± 10 °C until analysis. All blood samples were light-proof, from collecting to processing and storage.

An enantioselective method was developed and validated for the simultaneous determination of dexlansoprazole and S-lansoprazole in human plasma by chiral liquid chromatography with tandem mass spectrometry \[[@CR10]\]. This method was applied to the present pharmacokinetic study. Specifically, lansoprazole enantiomers and internal standard (d4-lansoprazole) were extracted from plasma using acetonitrile as the protein-precipitating agent. Baseline chiral separation was achieved within 8.0 min on a Chiralpak IC column (150 mm × 4.6 mm, 5 µm) with a column temperature of 30 °C. The mobile phase consisted of 10 mM ammonium acetate solution containing 0.05% acetic acid/acetonitrile (50:50, v/v). Mass spectrometric analysis was performed using an API 4000 mass spectrometer coupled with an electrospray ionization source in positive ion mode. Multiple reaction monitoring transitions of m/z 370.1→252.0 and 374.1→252.0 were used to quantify lansoprazole enantiomers and d4-lansoprazole, respectively. For each enantiomer, no apparent matrix effect was found, the calibration curve was linear over 5.00--4000 ng/mL, the intra- and interday precisions were below 8.0%, and the accuracy was − 2.9 to 10.05%.

Pharmacodynamic Measurement {#Sec7}
---------------------------

To assess the pharmadynamic effect, an ambulatory pH measurement system (Orion II; Medical Measurement Systems B.V., Enschede, The Netherlands) with a disposable pH catheter (pHersaflex; Medical Measurement Systems B.V., Enschede, The Netherlands) was used to monitor intragastric pH. A baseline pH profile was obtained prior to intravenous administration of dexlansoprazole or lansoprazole on day 0, followed by intragastric pH monitoring on day 1 (first dose) and day 5. The intragastric pH data were recorded continuously for 24 h at baseline and for 24 h after a single dose and the last morning dose. Data were stored in the MMS Database (including the Measurement and Analysis Program, MMS, The Netherlands) for later analysis.

Safety Assessment {#Sec8}
-----------------

Safety assessment, including changes in vital signs and laboratory tests, physical examination findings, and incidence or reports of adverse events (AEs), were performed as scheduled in the protocol. Any AEs occurring during the study were collected by physicians from direct observation, spontaneous reports by volunteers, medical conditions and nonspecific inquiry, and closely followed to satisfactory resolution. The severity of AEs was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, and the relationship to study treatment (possibly related, not possibly related) was also assessed.

Pharmacokinetic/Pharmacodynamic and Statistical Analysis {#Sec9}
--------------------------------------------------------

The maximum measured concentration over the sampling period (*C*~max~) was obtained directly from the observed data. The pharmacokinetic parameters AUC from time zero to infinity (AUC~∞~), AUC from time zero to the last measurable concentration (AUC~t~), total CL, *V*~d~, and elimination half-life (*t*~½~) were determined using a noncompartmental method with Phoenix WinNonlin software, version 6.3 (Pharsight Corporation, Sunnyvale, CA, USA). Pharmacodynamic parameters, including median pH, mean pH, percentage of time with the intragastric pH above 4.0 \[TpH ≥ 4.0(%)\], percentage of time with the intragastric pH above 6.0 \[TpH ≥ 6.0(%)\], and baseline-adjusted intragastric pH parameters were calculated using the MMS software, and compared according to the time intervals of 0--24, 0--4, 0--12, and 12--24 h postdosing. Statistical analysis was performed using SAS^**®**^ version 9.4 software (SAS Institute, Cary, NC, USA). One-way analysis of variance (ANOVA) or the Wilcoxon rank-sum test after a normality test were used to assess the differences, and a *p* value \< 0.05 was considered statistically significant. Pearson's correlation coefficient was calculated to assess the pharmacokinetic/pharmacodynamic relationship.

Results {#Sec10}
=======

Subject Baseline Characteristics {#Sec11}
--------------------------------

As shown in Fig. [1](#Fig1){ref-type="fig"}, a total of 262 healthy Chinese adult volunteers were screened from June to September 2017. Ultimately, 70 participants were enrolled, with seven males and seven females in each group. Table [1](#Tab1){ref-type="table"} summarizes the demographic characteristics of the subjects. No statistically significant differences in baseline demographics were found among the groups.Fig. 1Study screening, enrollment, dosing and follow-up. All 70 participants completed the study regimenTable 1Demographic characteristics of the study subjects \[*n* = 70\]CharacteristicDexlansoprazole groupLansoprazole groupA (15 mg qd)B (15 mg q12h)C (30 mg qd)D (30 mg q12h)E (30 mg q12h)No. of subjects1414141414Age, years Mean (SD)29.1 (8.51)26.9 (4.66)25.3 (4.25)27.9 (5.04)29.6 (6.10) Minimum--maximum19--4519--3619--3320--4019--43Weight, kg Mean (SD)63.2 (11.14)61.4 (7.84)58.6 (6.74)59.8 (8.38)57.7 (6.90) Minimum--maximum46.3--78.247.6--75.348.7--72.248.8--81.545.3--68.5Height, cm Mean (SD)165.2 (9.05)167.9 (5.40)164.0 (3.98)165.1 (6.94)161.4 (7.15) Minimum--maximum150.0--180.0157.0--176.0156.0--170.0151.0--175.0146.0--177.0BMI, kg/m^2^ Mean (SD)22.9 (2.08)21.7 (2.21)21.7 (1.81)21.8 (1.88)22.1 (1.74) Minimum--maximum19.8--25.819.1--25.019.0--25.219.5--26.620.3--25.2*BMI* body mass index, *SD* standard deviation, *qd* once daily, *q12h* every 12 h

Pharmacokinetic Properties {#Sec12}
--------------------------

All subjects completed the whole study and were included in the pharmacokinetic analyses. For single-dose pharmacokinetic evaluation, we combined groups A and B as a single-dose group of dexlansoprazole 15 mg, while groups C and D were combined into another single-dose group of dexlansoprazole 30 mg. The mean plasma concentration-time profiles of dexlansoprazole obtained after single intravenous administration of dexlansoprazole 15 or 30 mg and lansoprazole 30 mg are shown in Fig. [2](#Fig2){ref-type="fig"}. The major pharmacokinetic parameters of dexlansoprazole are summarized in Table [2](#Tab2){ref-type="table"}. An increase in dexlansoprazole dose from 15 to 30 mg resulted in a dose-proportional increase in *C*~max~ and AUC following a single intravenous administration. The *t*~½~, CL and *V*~d~ parameters were independent of dose. No S-lansoprazole was detectable in plasma following intravenous administration of dexlansoprazole, therefore racemic conversion of dexlansoprazole to S-lansoprazole did not occur. After intravenous infusion of lansoprazole, dexlansoprazole was the major isomer in the plasma, while S-lansoprazole displayed a rapid CL, with *t*~½~ being approximately 1 h. Compared with dexlansoprazole 15 mg, administration of lansoprazole 30 mg resulted in a statistically significant increase in both AUC~t~ (*p* *=* 0.026) and AUC~∞~ (*p* *=* 0.037) of dexlansoprazole. After multiple intravenous doses, the *C*~max~ and AUC parameters remained similar to those of the single dose on day 1, indicating that dexlansoprazole was not accumulating after repeated administration. The major pharmacokinetic parameters after repeated administration are summarized in Table [3](#Tab3){ref-type="table"}. Consistent with the results from a single dose, AUC~t~ and *V*~d~ of dexlansoprazole in the lansoprazole 30 mg group were also significantly higher than in the dexlansoprazole 15 mg group with repeated administration.Fig. 2Mean plasma concentration-time profiles after single intravenous administration of dexlansoprazole 15 or 30 mg and lansoprazole 30 mg. **a** Linear scale; **b** semi-logarithmic scaleTable 2Pharmacokinetic parameters after single intravenous administration of dexlansoprazole 15 or 30 mg and lansoprazole 30 mg (mean ± SD)ParameterDexlansoprazole groupLansoprazole groupA \[*N* *=* 14\]B \[*N* *=* 14\]15 mg \[*N* *=* 28\]C \[*N* *=* 14\]D \[*N* *=* 14\]30 mg \[*N* *=* 28\]E \[*N* *=* 14\]DexlansoprazoleS-lansoprazole*C*~max~, ng/mL1534.86 ± 271.921490.00 ± 201.451512.43 ± 235.933242.14 ± 485.273145.64 ± 296.213193.89 ± 397.551663.50 ± 264.11848.13 ± 254.13*t*~½~, h2.00 ± 1.291.52 ± 0.641.76 ± 1.032.07 ± 1.522.04 ± 1.282.06 ± 1.382.32 ± 1.741.02 ± 0.62MRT~t~2.28 ± 0.971.88 ± 0.732.08 ± 1.032.30 ± 1.022.34 ± 0.922.32 ± 0.962.50 ± 1.021.02 ± 0.64AUC~t~, ng·h/mL3706.33 ± 1842.632956.61 ± 1259.203331.47 ± 1594.978504.36 ± 5251.327705.40 ± 3352.638104.88 ± 4342.224787.40 ± 2461.01^a^(*p* *=* 0.026)1140.25 ± 829.56AUC~∞~, ng·h/mL3973.77 ± 2373.663022.23 ± 1363.573498.00 ± 1960.309380.59 ± 7219.508206.10 ± 4318.428793.35 ± 5867.885372.52 ± 3709.23^a^(*p* *=* 0.037)1161.07 ± 848.87*V*~d~, L11.00 ± 1.5111.31 ± 1.8911.16 ± 1.6910.03 ± 1.5510.57 ± 1.2810.30 ± 1.4218.64 ± 2.97^a^(*p* *=* 0.000)43.65 ± 24.30CL, L/h4.90 ± 2.365.90 ± 2.435.40 ± 2.414.65 ± 2.624.39 ± 1.634.52 ± 2.147.49 ± 3.57^a^(*p* *=* 0.030)34.66 ± 15.36Data are expressed as arithmetic mean ± SDFor single-dose pharmacokinetic evaluation, we combined groups A and B as a single-dose group of dexlansoprazole 15 mg (*N* *=* 28), while groups C and D were combined as a single-dose group of dexlansoprazole 30 mg (*N* *=* 28)*SD* standard deviation, *C*~*max*~ maximum measured concentration over the sampling period, *t*~*½*~ apparent elimination half-life, *MRT*~*t*~ mean retention time, *AUC*~*t*~ area under the concentration-time curve from time zero to the last measurable concentration, *AUC*~*∞*~ area under the concentration-time curve from time zero to infinity, *V*~*d*~ volume of distribution, *CL* total clearance^a^Compared with single-dose dexlansoprazole 15 mgTable 3Pharmacokinetic parameters after repeated intravenous administration of dexlansoprazole 15 or 30 mg and lansoprazole 30 mg (mean ± SD)ParameterDexlansoprazole groupLansoprazole groupA (15 mg qd)B (15 mg q12h)C (30 mg qd)D (30 mg q12h)E (30 mg q12h)DexlansoprazoleS-lansoprazole*C*~max~, ng/mL1583.50 ± 234.171700.36 ± 696.323518.64 ± 1245.553068.29 ± 258.061792.43 ± 326.01811.63 ± 181.98*t*~½~, h2.13 ± 1.631.66 ± 0.922.06 ± 1.302.07 ± 1.272.43 ± 1.690.87 ± 0.58MRT~t~2.88 ± 2.172.15 ± 1.212.84 ± 1.972.87 ± 1.903.42 ± 2.491.11 ± 0.76AUC~t~, ng·h/mL3860.13 ± 1964.933228.494 ± 1935.458878.77 ± 5518.358389.95 ± 4581.115845.45 ± 3916.79^a^(*p* *=* 0.034)1165.52 ± 920.46AUC~∞~, ng·h/mL4202.46 ± 2697.973370.36 ± 2285.629690.00 ± 7358.789071.59 ± 6009.336690.33 ± 5708.481180.29 ± 942.84*V*~d~, L10.19 ± 1.4710.26 ± 1.349.25 ± 1.579.88 ± 1.1817.41 ± 2.20^a^(*p* *=* 0.000)30.55 ± 6.17CL, L/h4.72 ± 2.205.9 ± 2.644.42 ± 2.414.37 ± 1.777.02 ± 3.6935.98 ± 17.51Accumulation index1.01 ± 0.031.02 ± 0.051.01 ± 0.011.04 ± 0.081.06 ± 0.121.00 ± 0.01*SD* standard deviation, *C*~*max*~ maximum measured concentration over the sampling period, *t*~*½*~ elimination half-life, *MRT*~*t*~ mean retention time, *AUC*~*t*~ area under the concentration-time curve from time zero to the last measurable concentration, *AUC*~*∞*~ area under the concentration-time curve from time zero to infinity, *V*~*d*~ volume of distribution, *CL* total clearance, *qd* once daily, *q12h* every 12 h^a^Compared with group B (dexlansoprazole 15 mg q12h)

Pharmacodynamic Properties {#Sec13}
--------------------------

As shown in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}, the baseline median and mean intragastric pH was 1.44--1.91 and 1.76--2.37, respectively. No statistically significant differences in baseline intragastric pH were found among the groups. After intravenous administration of dexlansoprazole or lansoprazole, intragastric pH was significantly elevated in subjects across all groups. Changes in percentage time with the intragastric pH ≥ 4.0 or pH ≥ 6.0, TpH ≥ 4.0(%) or TpH ≥ 6.0(%), after intravenous administration of dexlansoprazole or lansoprazole, are shown in Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}.Table 4Change in intragastric median pH after single or repeated intravenous administration of dexlansoprazole 15 or 30 mg and lansoprazole 30 mg (mean ± SD)Time periodVariableDexlansoprazole groupLansoprazole group*p* valueA (15 mg qd)B (15 mg q12h)C (30 mg qd)D (30 mg q12h)E (30 mg q12h)0--24 hBaseline1.54 ± 0.231.53 ± 0.191.57 ± 0.181.76 ± 0.701.54 ± 0.130.3558First dose (day 1)4.73 ± 1.125.88 ± 0.785.36 ± 1.506.15 ± 0.855.97 ± 1.040.0081Baseline-adjusted3.19 ± 1.064.35 ± 0.753.79 ± 1.454.39 ± 0.964.44 ± 0.970.0139Last dose (day 5)4.63 ± 1.236.07 ± 0.615.69 ± 1.026.34 ± 0.456.15 ± 0.62\< 0.0001Baseline-adjusted3.25 ± 1.044.54 ± 0.694.12 ± 1.174.56 ± 0.924.61 ± 0.620.00090--12 hBaseline1.75 ± 0.441.76 ± 0.321.61 ± 0.331.91 ± 0.611.76 ± 0.280.4595First dose (day 1)5.92 ± 0.775.72 ± 1.246.46 ± 1.326.28 ± 0.935.99 ± 1.040.3967Baseline-adjusted4.17 ± 0.673.96 ± 1.284.85 ± 1.294.36 ± 0.964.23 ± 1.120.2795Last dose (day 5)5.95 ± 0.726.11 ± 0.786.63 ± 0.426.50 ± 0.336.54 ± 0.560.0134Baseline-adjusted4.27 ± 0.714.35 ± 0.795.02 ± 0.724.57 ± 0.694.77 ± 0.630.053512--24 hBaseline1.45 ± 0.191.44 ± 0.211.54 ± 0.171.66 ± 0.761.46 ± 0.140.4992First dose (day 1)3.58 ± 1.505.89 ± 0.804.27 ± 1.826.24 ± 1.005.89 ± 1.14\< 0.0001Baseline-adjusted2.12 ± 1.474.45 ± 0.732.74 ± 1.774.57 ± 1.214.44 ± 1.05\< 0.0001Last dose (day 5)3.44 ± 1.715.83 ± 0.654.32 ± 1.636.05 ± 0.615.71 ± 0.79\< 0.0001Baseline-adjusted2.12 ± 1.644.39 ± 0.652.78 ± 1.704.38 ± 1.114.25 ± 0.80\< 0.00010--4 hBaseline1.55 ± 0.271.42 ± 0.201.71 ± 0.731.69 ± 0.571.63 ± 0.390.4826First dose (day 1)3.95 ± 1.864.11 ± 1.555.48 ± 1.775.24 ± 1.733.94 ± 1.330.0304Baseline-adjusted2.41 ± 1.752.69 ± 1.513.76 ± 1.693.54 ± 1.612.31 ± 1.240.0495*p* values represent the comparison among the five groups*SD* standard deviation, *qd* once daily, *q12h* every 12 hTable 5Change in intragastric mean pH after single or repeated intravenous administration of dexlansoprazole 15 or 30 mg and lansoprazole 30 mg (mean ± SD)Time periodVariableDexlansoprazole groupLansoprazole group*p* valueA (15 mg qd)B (15 mg q12h)C (30 mg qd)D (30 mg q12h)E (30 mg q12h)0--24 hBaseline2.07 ± 0.462.09 ± 0.312.01 ± 0.372.17 ± 0.742.03 ± 0.250.9031First dose (day 1)4.72 ± 0.845.54 ± 0.735.28 ± 1.156.01 ± 0.805.66 ± 0.770.0051Baseline-adjusted2.65 ± 0.773.44 ± 0.763.26 ± 1.013.84 ± 0.873.63 ± 0.790.0073Last dose (day 5)4.66 ± 0.915.70 ± 0.765.26 ± 0.886.15 ± 0.505.88 ± 0.670.0001Baseline-adjusted2.68 ± 0.753.61 ± 0.863.24 ± 1.133.96 ± 0.893.85 ± 0.650.00210--12 hBaseline2.28 ± 0.452.37 ± 0.252.14 ± 0.442.34 ± 0.622.29 ± 0.360.7042First dose (day 1)5.41 ± 0.605.36 ± 0.916.10 ± 1.035.91 ± 0.855.54 ± 0.680.0898Baseline-adjusted3.13 ± 0.532.99 ± 1.033.96 ± 0.903.57 ± 1.003.26 ± 0.880.0432Last dose (day 5)5.59 ± 0.715.73 ± 0.886.09 ± 0.626.22 ± 0.476.15 ± 0.590.0609Baseline-adjusted3.38 ± 0.653.36 ± 0.893.93 ± 1.003.88 ± 0.693.86 ± 0.740.164912--24 hBaseline1.83 ± 0.621.81 ± 0.491.87 ± 0.352.06 ± 0.971.76 ± 0.370.7342First dose (day 1)4.04 ± 1.125.69 ± 0.844.45 ± 1.536.09 ± 0.895.79 ± 0.95\< 0.0001Baseline-adjusted2.21 ± 1.153.87 ± 0.742.58 ± 1.394.04 ± 1.134.03 ± 0.83\< 0.0001Last dose (day 5)3.73 ± 1.305.64 ± 0.804.43 ± 1.256.07 ± 0.575.60 ± 0.87\< 0.0001Baseline-adjusted2.00 ± 1.223.83 ± 0.982.55 ± 1.393.98 ± 1.143.84 ± 0.77\< 0.00010--4 hBaseline2.13 ± 0.381.81 ± 0.322.20 ± 0.752.11 ± 0.622.06 ± 0.310.3324First dose (day 1)4.12 ± 1.254.32 ± 1.165.46 ± 1.375.21 ± 1.364.16 ± 0.800.0082Baseline-adjusted1.98 ± 1.132.51 ± 1.213.26 ± 1.153.10 ± 1.322.11 ± 0.840.0126*p* values represent the comparison among the five groups*SD* standard deviation, *qd* once daily, *q12h* every 12 hTable 6Change in percentage time with the intragastric pH ≥ 4.0 after single or repeated intravenous administration of dexlansoprazole 15 or 30 mg and lansoprazole 30 mg (mean ± SD)Time periodVariableDexlansoprazole groupLansoprazole group*p* valueA (15 mg qd)B (15 mg q12h)C (30 mg qd)D (30 mg q12h)E (30 mg q12h)0--24 hBaseline10.12 ± 7.3011.21 ± 6.758.47 ± 5.6611.46 ± 13.188.56 ± 5.850.8000First dose (day 1)61.14 ± 16.3276.31 ± 11.9867.34 ± 20.9286.17 ± 11.5279.69 ± 15.300.0007Baseline-adjusted51.02 ± 15.0265.11 ± 14.5058.86 ± 19.2374.71 ± 13.3371.13 ± 18.490.0025Last dose (day 5)61.45 ± 18.9283.58 ± 12.3470.14 ± 15.6593.39 ± 5.9787.26 ± 12.08\< 0.0001Baseline-adjusted53.04 ± 16.8172.37 ± 15.1561.38 ± 19.2081.44 ± 13.8378.70 ± 12.77\< 0.00010--12 hBaseline14.05 ± 8.9815.34 ± 7.6511.84 ± 7.4812.89 ± 11.1213.21 ± 9.040.8765First dose (day 1)73.47 ± 9.6371.26 ± 15.7980.52 ± 15.9282.36 ± 13.1473.81 ± 12.680.1505Baseline-adjusted59.42 ± 7.7855.92 ± 19.6768.68 ± 13.7869.47 ± 17.5860.60 ± 19.250.1279Last dose (day 5)79.22 ± 12.5283.01 ± 13.2385.37 ± 11.1292.85 ± 7.2989.92 ± 10.010.0172Baseline-adjusted66.68 ± 14.8867.66 ± 14.9773.04 ± 16.6679.72 ± 11.2576.71 ± 15.850.118512--24 hBaseline6.20 ± 9.897.05 ± 9.795.09 ± 4.7610.51 ± 17.333.91 ± 6.170.5358First dose (day 1)48.70 ± 24.8581.31 ± 13.7454.09 ± 29.8689.96 ± 11.5785.54 ± 20.04\< 0.0001Baseline-adjusted42.50 ± 25.4574.26 ± 14.4948.99 ± 28.2679.46 ± 15.4981.62 ± 20.17\< 0.0001Last dose (day 5)43.64 ± 29.6784.08 ± 13.5854.85 ± 22.9993.88 ± 6.1584.54 ± 17.03\< 0.0001Baseline-adjusted39.35 ± 28.7177.03 ± 18.2649.66 ± 25.0882.58 ± 18.1380.63 ± 15.68\< 0.00010--4 hBaseline12.55 ± 6.216.73 ± 5.3112.48 ± 11.259.64 ± 9.498.71 ± 6.350.2698First dose (day 1)44.02 ± 25.7349.81 ± 25.1867.31 ± 25.1868.33 ± 26.2547.26 ± 19.250.0218Baseline-adjusted31.47 ± 25.3543.08 ± 26.0054.84 ± 20.9858.69 ± 26.2338.54 ± 21.900.0254*p* values represent the comparison among the five groups*SD* standard deviation, *qd* once daily, *q12h* every 12 hTable 7Change in percentage time with the intragastric pH ≥ 6.0 after single or repeated intravenous administration of dexlansoprazole 15 or 30 mg and lansoprazole 30 mg (mean ± SD)Time periodVariableDexlansoprazole groupLansoprazole group*p* valueA (15 mg qd)B (15 mg q12h)C (30 mg qd)D (30 mg q12h)E (30 mg q12h)0--24 hBaseline3.36 ± 4.922.89 ± 2.732.54 ± 2.733.20 ± 4.392.60 ± 2.860.9684First dose (day 1)36.52 ± 14.7249.81 ± 17.2948.56 ± 23.2158.89 ± 20.4351.99 ± 16.300.0496Baseline-adjusted33.16 ± 14.2246.93 ± 17.1546.03 ± 21.9855.69 ± 18.6549.39 ± 16.310.0320Last dose (day 5)35.70 ± 16.1753.70 ± 17.0649.99 ± 17.9262.62 ± 15.3257.00 ± 16.350.0013Baseline-adjusted33.45 ± 13.8550.81 ± 16.6347.38 ± 19.3459.20 ± 15.6254.40 ± 15.610.00230--12 hBaseline2.58 ± 2.613.62 ± 2.653.15 ± 3.732.71 ± 3.382.80 ± 3.440.9169First dose (day 1)51.90 ± 15.6849.68 ± 19.7465.66 ± 22.0259.89 ± 19.8353.36 ± 12.950.1458Baseline-adjusted49.32 ± 15.1246.06 ± 21.0362.51 ± 20.9957.18 ± 20.5250.56 ± 14.420.1512Last dose (day 5)53.06 ± 17.1656.18 ± 21.1868.25 ± 14.3668.85 ± 12.6966.26 ± 15.260.0370Baseline-adjusted51.29 ± 15.7452.56 ± 21.0964.91 ± 16.7666.00 ± 11.2263.46 ± 15.950.053812--24 hBaseline4.12 ± 8.422.12 ± 4.151.93 ± 3.034.17 ± 7.602.42 ± 4.850.7534First dose (day 1)21.14 ± 15.2749.96 ± 21.7531.42 ± 28.1057.83 ± 26.2250.61 ± 23.240.0005Baseline-adjusted17.02 ± 16.6147.84 ± 20.0929.49 ± 26.6553.66 ± 24.3848.19 ± 21.710.0002Last dose (day 5)18.35 ± 19.0551.18 ± 19.2431.68 ± 23.8756.35 ± 19.5747.74 ± 20.07\< 0.0001Baseline-adjusted15.63 ± 17.8349.06 ± 18.3629.82 ± 24.4651.86 ± 21.3845.31 ± 18.53\< 0.00010--4 hBaseline2.90 ± 3.542.88 ± 3.735.39 ± 7.003.55 ± 4.782.69 ± 3.310.5385First dose (day 1)28.15 ± 24.6430.44 ± 19.6152.01 ± 28.2947.79 ± 28.8224.52 ± 16.420.0089Baseline-adjusted25.25 ± 24.1427.56 ± 20.2246.62 ± 25.1644.24 ± 28.2821.84 ± 18.300.0158*p* values represent the comparison among the five groups*SD* standard deviation, *qd* once daily, *q12h* every 12 h

During a 0--12 h interval, a single dose of dexlansoprazole 15 mg (group B) and 30 mg (group D) resulted in a median intragastric pH of 5.72 ± 1.24 and 6.28 ± 0.93, mean intragastric pH of 5.36 ± 0.91 and 5.91 ± 0.85, TpH ≥ 4.0(%) of 71.26 ± 15.79 and 82.36 ± 13.14, and TpH ≥ 6.0(%) of 49.68 ± 19.74 and 59.89 ± 19.83, respectively. In the lansoprazole 30 mg group (group E), median and mean intragastric pH, TpH ≥ 4.0(%) and TpH ≥ 6.0(%) 0--12 h after the first dose were 5.99 ± 1.04, 5.54 ± 0.68, 73.81 ± 12.68, and 53.36 ± 12.95, respectively. There were no statistically significant differences in pharmacodynamic parameters 0--12 h after a single dose among these three groups.

After repeated administration, all pharmacodynamic parameters showed an increase from the first dose on day 1 to the last morning dose on day 5, which indicated further gastric acid suppression. The mean intragastric pH 0--12 h after the last morning dose of dexlansoprazole 15 mg (group B) or 30 mg (group D), or lansoprazole 30 mg (group E), was 5.73 ± 0.88, 6.22 ± 0.47, and 6.15 ± 0.59, respectively. The median intragastric pH, TpH ≥ 4.0(%) and TpH ≥ 6.0(%) 0--12 h after the last morning dose in group B was 6.11 ± 0.78, 83.01 ± 13.23 and 56.18 ± 21.18, respectively, which were similar to those in group E, i.e. 6.54 ± 0.56, 89.92 ± 10.01 and 66.26 ± 15.26, respectively. The median intragastric pH, TpH ≥ 4.0(%) and TpH ≥ 6.0(%) in group D was 6.50 ± 0.33, 92.85 ± 7.29 and 68.85 ± 12.69, respectively. Zero to 24 h after the last morning dose, median and mean intragastric pH, TpH ≥ 4.0(%) and TpH ≥ 6.0(%) in group B were 6.07 ± 0.61, 5.70 ± 0.76, 83.58 ± 12.34 and 53.70 ± 17.06, respectively, which were also similar to those in group E, i.e. 6.15 ± 0.62, 5.88 ± 0.67, 87.26 ± 12.08 and 57.00 ± 16.35, respectively. An increment was found in the median and mean intragastric pH, TpH ≥ 4.0(%) and TpH ≥ 6.0(%) in group D compared with group B, i.e. 6.34 ± 0.45, 6.15 ± 0.50, 93.39 ± 5.97 and 62.62 ± 15.32, respectively. However, no statistically significant difference of all the pharmacodynamic parameters was observed among these three groups.

No significant differences in baseline-adjusted median and mean intragastric pH, baseline-adjusted TpH ≥ 4.0(%) and TpH ≥ 6.0(%) were observed between groups B and E during any intervals. Baseline-adjusted median and mean intragastric pH, TpH ≥ 4.0(%) and TpH ≥ 6.0(%) for group D were significantly higher than those of group B, but only 0--4 h after the first dose.

Pharmacokinetic/Pharmacodynamic Relationship {#Sec14}
--------------------------------------------

The pharmacokinetic/pharmacodynamic relationship between dexlansoprazole AUC~t~ and baseline-adjusted TpH ≥ 4.0(%) or TpH ≥ 6.0(%) 0--12 h after a single dose was assessed by putting all the data from the dexlansoprazole groups together, and excluding the lansoprazole group. Three cases with an AUC~t~ \> 15,000 ng·h/mL were excluded directly from the scatter diagram. As shown in Fig. [3](#Fig3){ref-type="fig"}, there was a moderate positive correlation between AUC~t~ and baseline-adjusted TpH ≥ 4.0(%) or TpH ≥ 6.0(%) over 0--12 h, with Pearson correlation coefficients of 0.604 and 0.480, respectively (*p* *=* 0.000). After q12h multiple dosing, a weak positive correlation between dexlansoprazole AUC~t~ and baseline-adjusted TpH ≥ 4.0(%) over 0--24 h was observed, as shown in Fig. [4](#Fig4){ref-type="fig"}, with a Pearson correlation coefficient of 0.437 (*p* *=* 0.029), while the correlation between AUC~t~ and baseline-adjusted TpH ≥ 6.0(%) over 0--24 h was not evaluated as the TpH ≥ 6.0(%) data were non-normally distributed.Fig. 3Correlation of dexlansoprazole AUC~t~ and baseline-adjusted **a** TpH ≥ 4.0(%) or **b** TpH ≥ 6.0(%) 0--12 h after a single administration. *AUC*~*t*~ area under the concentration-time curve from time zero to the last measurable concentration, *TpH≥4.0(%)* percentage of time with the intragastric pH above 4.0, *TpH≥6.0(%)* percentage of time with the intragastric pH above 6.0Fig. 4Correlation of dexlansoprazole AUC~t~ and baseline-adjusted TpH ≥ 4.0 (%) 0--24 h after multiple dosing. *AUC*~*t*~ area under the concentration-time curve from time zero to the last measurable concentration, *TpH ≥ 4.0 (%)* percentage of time with the intragastric pH above 4.0

Safety and Tolerability {#Sec15}
-----------------------

A total of 31 AEs were recorded in 19 subjects during the study period, 19 (61.3%) of which were identified through laboratory investigations. The vast majority of AEs (29/31, 93.5%) were transient and considered mild (grade 1). One case of transient nasal pain as a grade 2 AE was reported in group D (dexlansoprazole 30 mg q12h), which was considered to be possibly related to pH catheter placement and was spontaneously recovered without intervention. Another subject in group C (dexlansoprazole 30 mg qd) received 1 week of treatment with levofloxacin eye drops and systemic antibiotics due to conjunctivitis as a grade 2 AE, which was considered possibly not related to the drug because it happened prior to the administration of dexlansoprazole. The incidence of AEs is summarized in Table [8](#Tab8){ref-type="table"}. No SAEs were reported. No participant was withdrawn due to AEs and no consistent, clinically significant changes from baseline were observed in vital signs, physical examinations, laboratory test results or ECG.Table 8Summary of study adverse eventsAdverse eventDexlansoprazole groupLansoprazole groupA (15 mg qd)B (15 mg q12h)C (30 mg qd)D (30 mg q12h)E (30 mg q12h)Subjects with at least one AE \[*n* (%)\]3 (21.43)5 (35.71)3 (21.43)5 (35.71)3 (21.43)Number of AEs683104Fecal occult blood1331Urine-leukocytosis1Elevated white blood cell count2Elevated neutrophil count1Leukopenia1Neutropenia1Decreased hemoglobin1Elevated transaminase11Elevated uric acid1Decreased fibrinogen1Nasal pain1Upper respiratory infection1Conjunctivitis11Tendonitis1Palpitation1Fatigue1Nausea11Chest discomfort1Abdominal discomfort1Dry cough1*AE* adverse event, *qd* once daily, *q12h* every 12 h

Discussion {#Sec16}
==========

To date, a few studies have been conducted providing the evidence for controlling intragastric pH after intravenous infusion of dexlansoprazole developed by other pharmaceutical companies, but the original injection preparation of lansoprazole has never been used in these studies, and no clearly improved acid inhibition profile was noted \[[@CR11], [@CR12]\].

In this study, we examined the pharmacokinetic and pharmacodynamic characteristics of the dexlansoprazole injection in the context of single and multiple administration, compared with the original lansoprazole injection, and confirmed that the dexlansoprazole injection was safe and well-tolerated during continuous dosing, with AEs of low incidence and mild severity.

Freston et al. reported that the *C*~max~ and AUC of dexlansoprazole were approximately 1200 ng/mL and 2500 ng·h/mL, respectively, following intravenous infusion of lansoprazole 30 mg in Western healthy volunteers \[[@CR7]\]. It is well-known that a larger proportion of Asians have an impaired ability to metabolize PPIs than individuals of European and African descent, which would lead to higher PPI exposure (AUC and plasma levels) and more pronounced acid suppression effect in individuals of Asian ancestry \[[@CR13]\]. In fact, at the same regimen, we found that both dexlansoprazole *C*~max~ and AUC were even higher than in Western subjects, with *C*~max~ and AUC being approximately 1800 ng/mL and 5800 ng·h/mL, respectively. Consistent with these findings, results from our study showed that the *t*~½~ and CL of dexlansoprazole were 1.76--2.06 h and 4.52--5.40 L/h, respectively, which were similar to the findings in the study by Li et al. \[[@CR11]\], whereas the *t*~½~ of dexlansoprazole was 1.17--1.21 h and CL was 6.62--6.80 L/h in the study by Freston et al. The multiple dose pharmacokinetic parameters of R- or S-lansoprazole were similar to those observed following a single dose, indicating no accumulation after 5 days of q12h administration of dexlansoprazole or lansoprazole. Data from the lansoprazole 30 mg group showed that the plasma concentrations of S-lansoprazole declined rapidly, with a *t*~½~ of 0.87--1.02 h and a mean CL of approximately 35 L/h, which were consistent with those previous studies \[[@CR5], [@CR7], [@CR11]\].

Theoretically, lansoprazole, the racemic mixture, contains both the R- and S-enantiomer at the same equivalent, thus lansoprazole 30 mg has a comparable R-enantiomer dose as dexlansoprazole 15 mg. However, in the present study, AUC~t~ and *V*~d~ of dexlansoprazole were considerably higher in the lansoprazole 30 mg group than in the dexlansoprazole 15 mg group after either single or repeated administration, whereas the observed *C*~max~ of dexlansoprazole was similar. One possible reason for this finding is the limited number of individuals and the impact of interindividual variation due to metabolic phenotypes of *CYP2C19*, which is responsible for lansoprazole metabolism \[[@CR5], [@CR13]\]. Another possibility, i.e. the potential influence of S-lansoprazole in the delay of dexlansoprazole CL, has been proposed despite the fact that racemic conversion between dexlansoprazole and S-lansoprazole did not occur.

In pharmacodynamic evaluation, all pharmacodynamic parameters showed an obvious increase from baseline across all groups, indicating the definite gastric acid suppression achieved by administration of dexlansoprazole or lansoprazole. We did not design the lansoprazole once-daily dosing group, and, on the first dosing day, individuals in the lansoprazole 30 mg q12h group were administered the second dose just 12 h after the first dose. Therefore, intragastric pH levels over 0--24 h in such different conditions as lansoprazole cannot be compared with those in a single-dose situation. A single dose of dexlansoprazole 30 mg resulted in a mean 24-h intragastric pH of 5.28 ± 1.15, 24-h TpH ≥ 4.0(%) of 67.34 ± 12.34, and 24-h TpH ≥ 6.0(%) of 53.70 ± 17.06. These values were slightly lower than those reported by Li et al. partly due to the different manufacturers of dexlansoprazole. However, 0--24 h after q12h multiple dosing, mean intragastric pH for dexlansoprazole 30 mg was the highest (6.15 ± 0.62), followed by lansoprazole 30 mg (5.88 ± 0.67) and dexlansoprazole (5.70 ± 0.76). These findings were similar with the previous report by Li et al. \[[@CR11]\].

Increasing the dose frequency would improve acid suppression. As presumed, baseline-adjusted median and mean intragastric pH, TpH ≥ 4.0(%) and TpH ≥ 6.0(%) for the q12h groups were significantly higher than those of the once-daily groups. However, baseline-adjusted median and mean intragastric pH, TpH ≥ 4.0(%) and TpH ≥ 6.0(%) for the dexlansoprazole 30 mg group were significantly higher than those of the 15 mg group, but only 0--4 h after the first dose, suggesting that increasing the dose presented a transient better pH inhibition and had virtually little influence on whole-day gastric pH control. Although a statistically significant difference in dexlansoprazole AUC~t~ was noted between lansoprazole 30 mg and dexlansoprazole 15 mg, no significant differences in baseline-adjusted median and mean intragastric pH, TpH ≥ 4.0(%) and TpH ≥ 6.0(%) were observed between dexlansoprazole 15 mg and lansoprazole 30 mg during any intervals. It was proposed that the persistent inhibition effect of dexlansoprazole beyond its short plasma *t*~½~ \[[@CR14]\] contributed to decreasing the differences in pharmacodynamic parameters between dexlansoprazole 15 mg and lansoprazole 30 mg in the context of repeated administration as enhanced gastric acid inhibition was achieved after 5 days of q12h dosing in both groups. Other possible causes, such as individual variations in proton pump turnover and saturation of covalent binding to the proton pump \[[@CR14]\], should also be considered.

In addition, it is well-known that the degree of acid suppression was closely related to the total dose and the AUC \[[@CR14], [@CR15]\]. In our pharmacokinetic/pharmacodynamic relationship study, a positive correlation between AUC~t~ and baseline-adjusted TpH ≥ 4.0(%) 0--12 h after the first dose or 0--24 h after the last morning dose was noted, whereas there was no obvious correlation between AUC~t~ and baseline-adjusted TpH ≥ 6.0(%) 0--24 h after multiple dosing. This may be partly due to the full degree of gastric acid inhibition after multiple dosing of dexlansoprazole 15--30 mg, with TpH ≥ 4.0(%) and TpH ≥ 6.0(%) over 0--24 h being approximately 84--93% and 54--63%.

Limitations of our research are that the number of participants was limited and genotyping of *CYP2C19* was not performed prior to enrollment. The genotype variability of *CYP2C19* led to confusion in the difference in pharmacokinetic parameters between the dexlansoprazole and lansoprazole groups. In addition, given the different protein-binding characteristics between the isomers, it would be worthwhile to determine the pharmacokinetic characteristics using free dexlansoprazole or s-lansoprazole concentrations. Another possible limitation is that we cannot exclude the possibility that other factors may affect the pharmacokinetic and pharmacodynamic findings during the study period. Furthermore, healthy subjects may not exhibit the same therapeutic effect as patients with active bleeding. Furthermore, the pharmacokinetic and pharmacodynamic relationship is relatively weak, assuming a linear, direct concentration--effect relationship in our study. Other non-linear models, such as a mechanism-based pharmacokinetic/pharmacodynamic model \[[@CR16]\], which incorporates aspects of the physiological regulation of gastric acid production, the effects of food on gastric acid, and the complex effects of dexlansoprazole on gastric acid production, should be explored in order to predict optimal dosing regimens. Nevertheless, on the basis of our findings, we suggest that q12h dosing of dexlansoprazole 15 mg has a similar gastric acid suppression effect compared with q12h dosing of lansoprazole 30 mg, which provides a reliable basis to proceed with studies in patients with peptic ulcer bleeding disease or seriously disordered gastrointestinal function.

Conclusion {#Sec17}
==========

The present study has clearly demonstrated that twice-daily intravenous dosing of dexlansoprazole up to 30 mg was safe and well-tolerated in healthy Chinese subjects. Every 12 h dosing of dexlansoprazole 15 mg has the comparable effect of gastric acid inhibition as lansoprazole 30 mg twice daily.
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